translation agency

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update
Double Blind Randomized Placebo Controlled Trial of Adjunctive
Hakim, J. G.; Ternouth, I.; Mushangi, E.; et al.
August 24, 2000
Heart Online ( (08/00) Vol. 84, No. 2,

Researchers from Zimbabwe conducted a study to determine how adjunctive prednisolone affects the morbidity, pericardial fluid resolution, and mortality of HIV-seropositive patients with effusive tuberculous pericarditis. The study involved 58 patients between the ages of 18 and 55. Following a short course of antituberculous chemotherapy, the patients received treatment with prednisolone or placebo for six weeks. After 18 months, five patients who took prednisolone and 10 patients who took placebo had died. According to the researchers, patients randomized to receive prednisolone achieved a significantly quicker resolution of increased jugular venous pressure, hepatomegaly, and ascites. However, they note that the rate of radiologic and echocardiographic resolution of pericardial effusion was comparable in both groups.